Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-265246 is a potent and selective CDK1/2 inhibitor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 47.00 | |
5 mg | In stock | $ 113.00 | |
10 mg | In stock | $ 197.00 | |
25 mg | In stock | $ 389.00 | |
50 mg | In stock | $ 589.00 | |
100 mg | In stock | $ 843.00 | |
500 mg | In stock | $ 1,730.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 125.00 |
Description | BMS-265246 is a potent and selective CDK1/2 inhibitor. |
Targets&IC50 | CDK4-CyclinD:230 nM, CDK2-CyclinE:9 nM, CDK1-CyclinB:6 nM |
Kinase Assay | CDK1/Cyclin B1 Kinase Assay: Kinase reactions consists of 100 ng of baculovirus expressed GST-CDK1/cyclin B1 complex, 1 μg histone H1, 0.2 μCi 33P γ-ATP, 25 μM ATP in 50 μL of kinase buffer (50 mM Tris, pH 8.0, 10 mM MgCl2, 1 mM EGTA, 0.5 mM DTT). Reactions are incubated for 45 min at 30 °C and stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration of 15%. TCA precipitates are collected onto GF/C unifilter plates using a Filtermate universal harvester, and the filters are quantitated using a TopCount 96 well liquid scintillation counter. Dose response curves are generated to determine the concentration required to inhibit 50% of kinase activity (IC50). BMS265246 is dissolved at 10 mM in DMSO and evaluated at six concentrations, each in triplicate. The final concentration of DMSO in the assay equals 2%. IC50 values are derived by nonlinear regression analysis and have a coefficient of variance (SD/mean, n = 6) = 16%. |
Cell Research | HCT-116 cells are plated onto 96-well dishes. For each well, the cell density is calculated by counting the number of objects (cells) per field of view, and averaging across all fields for a given well. For a treatment compound, cell density is converted to a percentage relative to the plate-averaged cell density from DMSO treatment (i.e., 100% corresponds to the average cell density for DMSO treatment). Logistic regression curve fits are done using TIBCO Spotfire, and the concentration at which the curve crosses 50% is reported as the EC50 of BMS-265246.(Only for Reference) |
Synonyms | BMS265246 |
Molecular Weight | 345.34 |
Formula | C18H17F2N3O2 |
CAS No. | 582315-72-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 16 mg/mL (46.3 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BMS-265246 582315-72-8 Cell Cycle/Checkpoint CDK Pyrazolopyridine Inhibitor iTreg cell A2780 Angiotensin-converting Enzyme (ACE) MCF7 cells Cyclin dependent kinase inhibit CHI3L1 ovarian cancer BMS265246 Calu-3 cells BMS 265246 COVID-19 inhibitor